Yemen Violence Displaces 130,000 as Civilian Toll Rises 
OpenAI Agent Breaches Australia Medicare Data Portal 
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback 
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise 
France Keeps Top Health Alert as Officials Brace for Another Heatwave 
Taiwan Thanks US for Support Ahead of Trump-Xi Summit 
Trump Asks Supreme Court to Restore Third-Country Deportations 
Sudan Rejects US Legitimacy Remarks, Defends Sovereignty 
Venezuela Promises Elections as Delcy Rodriguez Pledges Democratic Transition 
US Invites Putin to Miami G20, Opening Door to Trump Summit 
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak 
3 clinical-grade skincare creams you really shouldn’t buy online 
Gaza Faces Evacuation Crisis as War-Damaged Buildings Risk Collapse 
NATO Boosts Intelligence Sharing Amid Russia Hybrid Threats 
Netanyahu Takes Aim at Mamdani as Israel Election Nears 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Add as a preferred source on Google
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) is facing leadership uncertainty after acting director Jeffery Taubenberger stepped down during ongoing Ebola and hantavirus outbreak concerns. The departure was revealed Thursday during a Senate hearing on the National Institutes of Health (NIH) 2027 budget, sparking criticism from Democratic lawmakers over the agency’s preparedness for emerging infectious diseases.
Taubenberger assumed the acting director role in April 2025 after the Trump administration removed former NIAID leadership. Senator Tammy Baldwin announced his resignation at the hearing, while Senator Patty Murray also referenced the sudden exit. NIH Director Jay Bhattacharya did not deny the reports and said the agency is shifting priorities away from civilian biodefense and pandemic preparedness toward direct infectious disease response, allergy research, and immunology.
The leadership change comes as global health officials monitor an Ebola outbreak in the Democratic Republic of Congo and potential hantavirus exposure linked to a luxury cruise ship outbreak in the Atlantic Ocean. Although no confirmed U.S. cases of Andes hantavirus have been reported, 41 individuals, including 18 people quarantined in Nebraska, remain under observation.
Former NIAID director Jeanne Marrazzo criticized the current situation, warning that the institute appears disconnected from researchers and pharmaceutical companies working on Ebola treatments. Under former director Anthony Fauci, NIAID played a major role in managing both the COVID-19 pandemic and the 2014-2016 Ebola crisis in West Africa.
The latest departures add to growing concerns about instability within the NIH, where more than half of its 27 institutes are currently overseen by acting directors. NIAID, the NIH’s second-largest institute with a budget exceeding $6.5 billion, remains central to U.S. infectious disease research and public health response efforts.
